Ronald M Salomon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6928451/publications.pdf

Version: 2024-02-01

56 3,240 papers citations

23 39
h-index g-index

60 60 docs citations

60 times ranked 3500 citing authors

#	Article	IF	CITATIONS
1	Slower perception of time in depressed and suicidal patients. European Neuropsychopharmacology, 2020, 40, 4-16.	0.7	16
2	600. Resting State fMRI of Raphe Nucleus Activity following Ketamine. Biological Psychiatry, 2017, 81, S243.	1.3	0
3	Evaluation of Voice Acoustics as Predictors of Clinical Depression Scores. Journal of Voice, 2017, 31, 256.e1-256.e6.	1.5	59
4	Disgust proneness and associated neural substrates in obesity. Social Cognitive and Affective Neuroscience, 2016, 11, 458-465.	3.0	21
5	Cross-corpus depression prediction from speech. , 2015, , .		7
6	Neuropsychological Effects of Deep Brain Stimulation in Subjects with Early Stage Parkinson's Disease in a Randomized Clinical Trial. Journal of Parkinson's Disease, 2015, 5, 151-163.	2.8	25
7	Effects of acute tryptophan depletion on raph \tilde{A} \otimes functional connectivity in depression. Psychiatry Research - Neuroimaging, 2015, 234, 164-171.	1.8	17
8	Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 731-737.	2.2	112
9	Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing. Psychopharmacology, 2013, 227, 41-54.	3.1	12
10	Increased oxidative stress in patients with depression and its relationship to treatment. Psychiatry Research, 2013, 206, 213-216.	3.3	80
11	Fourier reflections. Magnetic Resonance Imaging, 2013, 31, 634.	1.8	O
12	Oscillatory serotonin function in depression. Synapse, 2013, 67, 801-820.	1.2	22
13	Essential CNS Drug Development. Journal of Clinical Psychiatry, 2013, 74, e221.	2.2	O
14	Pilot Study Assessing the Feasibility of Applying Bilateral Subthalamic Nucleus Deep Brain Stimulation in Very Early Stage Parkinson's Disease: Study Design and Rationale. Journal of Parkinson's Disease, 2012, 2, 215-223.	2.8	18
15	Evidence for Chronically Altered Serotonin Function in the Cerebral Cortex of Female 3,4-Methylenedioxymethamphetamine Polydrug Users. Archives of General Psychiatry, 2012, 69, 399.	12.3	64
16	Deep brain stimulation in early Parkinson's disease: Enrollment experience from a pilot trial. Parkinsonism and Related Disorders, 2012, 18, 268-273.	2.2	47
17	MDMA (Ecstasy) association with impaired fMRI BOLD thalamic coherence and functional connectivity. Drug and Alcohol Dependence, 2012, 120, 41-47.	3.2	25
18	Time series fMRI measures detect changes in pontine raph \tilde{A} © following acute tryptophan depletion. Psychiatry Research - Neuroimaging, 2011, 191, 112-121.	1.8	29

#	Article	IF	Citations
19	Human Ecstasy Use is Associated with Increased Cortical Excitability: An fMRI Study. Neuropsychopharmacology, 2011, 36, 1127-1141.	5.4	23
20	Lishman's Organic Psychiatry, 4th ed Journal of Clinical Psychiatry, 2011, 72, 117-118.	2.2	0
21	Openness of patients' reporting with use of electronic records: psychiatric clinicians' views. Journal of the American Medical Informatics Association: JAMIA, 2010, 17, 54-60.	4.4	69
22	Cerebrospinal fluid sodium rhythms. Cerebrospinal Fluid Research, 2010, 7, 3.	0.5	46
23	Detecting Change in Biological Rhythms: A Multivariate Permutation Test Approach to Fourierâ€Transformed Data. Chronobiology International, 2009, 26, 258-281.	2.0	12
24	Prior MDMA (Ecstasy) use is associated with increased basal ganglia–thalamocortical circuit activation during motor task performance in humans: An fMRI study. NeuroImage, 2009, 46, 817-826.	4.2	27
25	Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. Menopause, 2009, 16, 644-652.	2.0	11
26	Psychophysiological States: The Ultradian Dynamics of Mind-Body Interactions. Journal of Clinical Psychiatry, 2009, 70, 1612-1613.	2.2	0
27	The Effects of Physical Quality of Life, Time, and Gender on Change in Symptoms of Anxiety and Depression after Liver Transplantation. Journal of Gastrointestinal Surgery, 2008, 12, 138-144.	1.7	44
28	Interpreting Tryptophan Depletion in Tobacco Smokers. Biological Psychiatry, 2008, 63, e29.	1.3	0
29	Estimation of Baseline Dopamine D2 Receptor Occupancy in Striatum and Extrastriatal Regions in Humans with Positron Emission Tomography with [18F] Fallypride. Biological Psychiatry, 2008, 63, 241-244.	1.3	50
30	Massachusetts General Hospital Comprehensive Clinical Psychiatry. Journal of Clinical Psychiatry, 2008, 69, 1988.	2.2	0
31	The American Psychiatric Publishing Textbook of Psychosomatic Medicine. Journal of Clinical Psychiatry, 2007, 68, 1990.	2.2	1
32	Central Neurochemical Ultradian Variability in Depression. Disease Markers, 2006, 22, 65-72.	1.3	5
33	Psychiatry, Psychonanalysis, and the New Biology of the Mind. Journal of Clinical Psychiatry, 2006, 67, 168.	2.2	0
34	Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression. Archives of General Psychiatry, 2005, 62, 409.	12.3	806
35	Treatment Enhances Ultradian Rhythms of CSF Monoamine Metabolites in Patients with Major Depressive Episodes. Neuropsychopharmacology, 2005, 30, 2082-2091.	5.4	14
36	Prevention of Relapse Following Cognitive Therapy vs Medications in Moderate to Severe Depression. Archives of General Psychiatry, 2005, 62, 417.	12.3	619

#	Article	IF	Citations
37	Functional and Neural Mechanism of Internval Timing. Journal of Clinical Psychiatry, 2005, 66, 1078-1079.	2.2	0
38	Introduction to Psychoneuroimmunology. Journal of Clinical Psychiatry, 2005, 66, 1496.	2.2	0
39	Efficacy, Safety, and Tolerability of Sertraline in Patients with Late-Life Depression and Comorbid Medical Illness. Journal of the American Geriatrics Society, 2004, 52, 86-92.	2.6	81
40	Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biological Psychiatry, 2003, 54, 96-104.	1.3	243
41	Association of a Critical CSF Tryptophan Threshold Level with Depressive Relapse. Neuropsychopharmacology, 2003, 28, 956-960.	5.4	26
42	Pilot Trial of Ondansetron in the Treatment of 8 Patients With Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2003, 64, 1025-1030.	2.2	56
43	Brain Circuitry and Signaling in Psychiatry. Journal of Clinical Psychiatry, 2003, 64, 737.	2.2	0
44	Defining Psychopathology in the 21st Century. Journal of Clinical Psychiatry, 2003, 64, 1399.	2.2	0
45	Serial cerebrospinal fluid tryptophan and 5-hydroxy indoleacetic acid concentrations in healthy human subjects. Life Sciences, 2002, 71, 1703-1715.	4.3	20
46	Models of the Mind. Journal of Clinical Psychiatry, 2002, 63, 80.	2.2	0
47	Rapid Eye Movement Sleep. Journal of Clinical Psychiatry, 2001, 62, 378.	2.2	0
48	Treatment for Chronic Deression. Journal of Clinical Psychiatry, 2000, 61, 684.	2.2	0
49	Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biological Psychiatry, 1999, 46, 212-220.	1.3	274
50	Ethics in Psychiatric Research. Journal of Clinical Psychiatry, 1999, 60, 560-561.	2.2	0
51	Lack of behavioral effects of monoamine depletion in healthy subjects. Biological Psychiatry, 1997, 41, 58-64.	1.3	7 5
52	Effects of α-Methyl-Para-Tyrosine (AMPT) in Drug-Free Depressed Patients. Neuropsychopharmacology, 1996, 14, 151-157.	5.4	61
53	Serotonin function in aggression: The effect of acute plasma tryptophan depletion in aggressive patients. Biological Psychiatry, 1994, 35, 570-572.	1.3	52
54	Effects of sleep deprivation on serotonin function in depression. Biological Psychiatry, 1994, 36, 840-846.	1.3	57

#	Article	lF	CITATIONS
55	The Effects of Tryptophan Depletion in Depression. Medical Science Symposia Series, 1993, , 211-222.	0.0	O
56	Rat cerebral cortical synaptoneurosomal membranes. Structure and interactions with imidazobenzodiazepine and 1,4-dihydropyridine calcium channel drugs. Biophysical Journal, 1990, 58, 513-531.	0.5	12